Literature DB >> 10098513

Activin and inhibin binding to the soluble extracellular domain of activin receptor II.

C J Donaldson1, J M Vaughan, A Z Corrigan, W H Fischer, W W Vale.   

Abstract

Activins and inhibins belong to the transforming growth factor-beta-like superfamily of growth and differentiation factors that exert pleiotropic effects in many target tissues. Heteromeric association of activin with two structurally related receptor serine/threonine kinases, activin receptor types I and II, initiates downstream signaling events. The extracellular domain of type II mouse activin receptor (ActRII ECD) was expressed in the baculovirus system, purified in three steps by lectin affinity, anion exchange, and reverse phase chromatography, and further characterized by mass spectrometry. The reduction in the apparent size of the purified ActRII ECD on SDS-PAGE after treatment with glycosidases provided evidence for N- and O-linked oligosaccharides. Specific receptor/ligand complexes of [125I] activin A to ActRII ECD or [125I]ActRII ECD to activin A were analyzed by cross-linking and immunoprecipitation. Two major radiolabeled bands were observed on SDS-PAGE with mobilities consistent with the expected size of ActRII ECD/betaA or ActRII ECD/betaAbetaA. When inhibin A was cross-linked to [125I]ActRII ECD, a slower migrating complex corresponding to ActRII ECD/betaAalpha was also observed. The apparent dissociation constant (Kd) for activin A binding to ActRII ECD was 2-7 nM. This Kd value is approximately an order of magnitude greater than that of the full-length membrane-associated type II receptor. Treatment of cultured rat anterior pituitary cells with ActRII ECD attenuated FSH secretion in response to exogenous activin A or endogenous activin B. These data indicate that the soluble ActRII ECD has structural determinants that are sufficient for high affinity ligand binding.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10098513     DOI: 10.1210/endo.140.4.6665

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  6 in total

1.  N-linked glycosylation of the bone morphogenetic protein receptor type 2 (BMPR2) enhances ligand binding.

Authors:  Jonathan W Lowery; Jose M Amich; Alex Andonian; Vicki Rosen
Journal:  Cell Mol Life Sci       Date:  2013-12-15       Impact factor: 9.261

Review 2.  Inhibin at 90: from discovery to clinical application, a historical review.

Authors:  Yogeshwar Makanji; Jie Zhu; Rama Mishra; Chris Holmquist; Winifred P S Wong; Neena B Schwartz; Kelly E Mayo; Teresa K Woodruff
Journal:  Endocr Rev       Date:  2014-07-22       Impact factor: 19.871

3.  BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II.

Authors:  T Kirsch; J Nickel; W Sebald
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

Review 4.  Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin.

Authors:  Kristy M Nicks; Daniel S Perrien; Nisreen S Akel; Larry J Suva; Dana Gaddy
Journal:  Mol Cell Endocrinol       Date:  2009-07-15       Impact factor: 4.102

5.  A soluble activin type IIA receptor induces bone formation and improves skeletal integrity.

Authors:  R Scott Pearsall; Ernesto Canalis; Milton Cornwall-Brady; Kathryn W Underwood; Brendan Haigis; Jeffrey Ucran; Ravindra Kumar; Eileen Pobre; Asya Grinberg; Eric D Werner; Vaida Glatt; Lisa Stadmeyer; Deanna Smith; Jasbir Seehra; Mary L Bouxsein
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-06       Impact factor: 11.205

6.  Activin potentiates proliferation in mature avian auditory sensory epithelium.

Authors:  Jennifer S McCullar; Sidya Ty; Sean Campbell; Elizabeth C Oesterle
Journal:  J Neurosci       Date:  2010-01-13       Impact factor: 6.167

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.